Respiratory Virus Vaccines on Deck for 2024
Respiratory vaccine R & D at Moderna, Merck, and Pfizer is focused on mRNA technology, added protection for vulnerable populations, and combination shots.
Pfizer BioNTech Topline Data Show Robust Immune Response for COVID-19/Influenza Vaccine Combination
The mRNA-based combination vaccine candidate for flu and COVID-19 received Fast Track Designation from the US Food and Drug Administration.